Home » News » 01/06 » UCB Pharmaceuticals sells bioproducts division for 120m euros

UCB Pharmaceuticals sells bioproducts division for 120m euros

Date published: 18/01/2006

UCB Pharmaceuticals is to sell its bioproducts manufacturing division to Swiss firm Lonza for 120 million euros. The division, based in Braine-l'Alleud near Brussels, has been active in chemical peptide manufacturing for over 20 years.

Lonza claims that the acquisition of the plant makes it "the only contract manufacturer with a historically successful track record of providing Active Pharmaceutical Ingredients (API)" using the three existing peptide technologies. Lonza chief executive Stefan Borgas said: "We are quite excited to welcome the fully dedicated, highly qualified and entrepreneurial UCB colleagues to join our global business.

"With this acquisition Lonza further strengthens its position as a worldwide leader in custom peptide manufacturing by continuing to develop the Braine-l'Alleud site as a global centre of excellence for the development and manufacture of peptides."

Roch Doliveux, UCB chief executive, said: "This transaction is another strategic move towards UCB's quest of becoming a global biopharmaceutical leader focusing on research, development, and commercialisation of therapeutic solutions for severe diseases.

"The reputation and strategic focus of Lonza as a leading contract manufacturer will enable the bioproducts division to further strengthen its leading position and join a group focused on custom manufacturing with whom UCB has several other long term manufacturing relationships."

© Adfero Ltd

Disclaimer

AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.